• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LifeSci Acquisition II Corp. (Amendment)

    9/16/21 4:24:29 PM ET
    $LSAQ
    Business Services
    Finance
    Get the next $LSAQ alert in real time by email
    SC 13G/A 1 lsaqa1_91621.htm COWEN AND COMPANY, LLC lsaqa1_91621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    LifeSci Acquisition II Corp
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    53229E103
    (CUSIP Number)
    May 10, 2021
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 53229E103
           
    1
    NAME OF REPORTING PERSON
    Cowen and Company, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    38-3698933
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    7,776
    6
    SHARED VOTING POWER
    7
    SOLE DISPOSITIVE POWER
    7,776
    8
    SHARED DISPOSITIVE POWER
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,776
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0.08%
    12
    TYPE OF REPORTING PERSON
    Passive Investor
    CUSIP No.: 53229E103
           
    1
    NAME OF REPORTING PERSON
    Cowen Financial Products LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    27-0423711
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    675,000
    6
    SHARED VOTING POWER
    7
    SOLE DISPOSITIVE POWER
    675,000
    8
    SHARED DISPOSITIVE POWER
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    675,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.74%
    12
    TYPE OF REPORTING PERSON
    Passive
    CUSIP No.: 53229E103
    ITEM 1(a). NAME OF ISSUER:
    LifeSci Acquisition II Corp
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    250 W 55th St.
    Suite 3401
    New York, NY 10019
    ITEM 2(a). NAME OF PERSON FILING:
    Cowen and Company, LLC
    Cowen Financial Products LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    599 Lexington Ave
    New York, NY 10022
    ITEM 2(c). CITIZENSHIP:
    USA
    USA
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    53229E103
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ ]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    682,776
    (b) Percent of class:
    6.82
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Cowen and Company, LLC : 7,776

    Cowen Financial Products LLC : 675,000
    (ii) shared power to vote or to direct the vote:
    Cowen and Company, LLC :

    Cowen Financial Products LLC :
    (iii) sole power to dispose or direct the disposition of:
    Cowen and Company, LLC : 7,776

    Cowen Financial Products LLC : 675,000
    (iv) shared power to dispose or to direct the disposition of:
    Cowen and Company, LLC :

    Cowen Financial Products LLC :
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 53229E103
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    September 16 2021
    Cowen and Company LLC
    By:
    /s/ John Holmes
    Name:
    John Holmes
    Title:
    Chief Operating Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $LSAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LSAQ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LSAQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE

    Science 37 to debut on Nasdaq as a publicly traded company under ticker symbol "SNCE"Business combination will provide Science 37 with approximately $235 million in cash proceeds to support continued growthScience 37 to fuel its mission to enable universal access to clinical research which has proven to accelerate patient enrollment, minimize patient burden, and include underserved patient populations Investments targeted to enhance the Science 37 Operating System to decentralize clinical trial execution and enable more agile clinical trials LOS ANGELES and NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Science 37, Inc., the Operating System for today's agile clinical trials, announced today

    10/7/21 8:00:00 AM ET
    $LSAQ
    Business Services
    Finance

    LifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination

    NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ:LSAQ), a blank check company formed for the purpose of pursuing targets that are focused on healthcare innovation, today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with Science 37, Inc. About LifeSci Acquisition II Corp. LifeSci Acquisition II Corp. (NASDAQ:LSAQ) is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganizat

    6/16/21 9:00:00 AM ET
    $LSAQ
    Business Services
    Finance

    Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future

    Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research $80 million via LifeSci Acquisition II Corp., a special purpose acquisition company with no public warrants $200 million via fully committed and upsized PIPE from leading institutional and strategic investors including Redmile Group; funds and accounts managed by BlackRock; Casdin Capital; dRx Capital (Novartis Pharma AG); LifeSci Venture Partners; Lux Capital; Mubadala Capital, the asset manageme

    5/7/21 7:55:00 AM ET
    $LSAQ
    Business Services
    Finance

    $LSAQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider De Silva Bhooshitha B.

    3 - Science 37 Holdings, Inc. (0001819113) (Issuer)

    10/18/21 4:48:37 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form 3: New insider Pharmaceutical Product Development, Llc claimed ownership of 17,314,315 shares

    3 - Science 37 Holdings, Inc. (0001819113) (Issuer)

    10/18/21 4:46:17 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form 3: New insider Lux Capital Management, Llc claimed ownership of 15,164,556 shares

    3 - Science 37 Holdings, Inc. (0001819113) (Issuer)

    10/18/21 4:32:23 PM ET
    $LSAQ
    Business Services
    Finance

    $LSAQ
    SEC Filings

    View All

    LifeSci Acquisition II Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - Science 37 Holdings, Inc. (0001819113) (Filer)

    10/13/21 5:26:13 PM ET
    $LSAQ
    Business Services
    Finance

    LifeSci Acquisition II Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure

    8-K - Lifesci Acquisition II Corp. (0001819113) (Filer)

    10/6/21 4:47:03 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form 424B3 filed by LifeSci Acquisition II Corp.

    424B3 - Lifesci Acquisition II Corp. (0001819113) (Filer)

    9/24/21 7:01:10 AM ET
    $LSAQ
    Business Services
    Finance

    $LSAQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by LifeSci Acquisition II Corp.

    SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)

    10/18/21 4:30:20 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form SC 13D filed by LifeSci Acquisition II Corp.

    SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)

    10/18/21 4:16:02 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form SC 13D filed by LifeSci Acquisition II Corp.

    SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)

    10/18/21 4:05:14 PM ET
    $LSAQ
    Business Services
    Finance